Key TakeawaysHims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply.The company makes compounded versions of weight-loss drugs under an FDA rule that applies when the originals are difficult to obtain.

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.